Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566488 · ClinicalTrials.gov registry record · Phase 1
Parathyroid and Thymus Transplantation in DiGeorge #931
A Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00566488: Completed Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
NCT00566488 is a Phase 1 study that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566488, a Phase 1 study, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess safety and tolerability of the procedures. This is a Phase 1, single site, open, non-randomized clinical protocol. Enrollment is closed and study intervention is complete for all enrolled subjects; but subjects continue for observation and follow-up. Subjects under 2 years old with complete DiGeorge syndrome (atypical or typical) received thymus transplantation. Subjects received pre-transplant immune suppression with rabbit anti-human-thymocyte-globulin. Subjects with hypoparathyroidism and an eligible parental donor received thymus and parental parathyroid transplantation. A primary hypothesis: Thymus/Parathyroid transplant subjects will need less calcium and/or calcitriol supplementation at 1 year post-transplant as compared to historical controls.
Primary Outcome
Subjects wtih complete DiGeorge anomaly who have received thymus and parathyroid transplants and survived to one year
Interventions
- BIOLOGICAL Thymus/Parathyroid Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
What the finished NCT00566488 record still lists
NCT00566488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Thymus/Parathyroid Transplantation is the first listed.
NCT00566488 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00566488 about?
NCT00566488 is a clinical study titled "Parathyroid and Thymus Transplantation in DiGeorge #931". This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess safety and tolerability of the procedures. This is a Phase 1, single site, o...
What is the current status of trial NCT00566488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2005-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00566488?
The interventions under investigation include: Thymus/Parathyroid Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00566488?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00566488's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia